참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|
| 반응물 | Cholesterol | HCID 5997 | — |
| 반응물 | Calcium Chloride | HCID 5284359 | — |
| 반응물 | Calcium | HCID 5460341 | — |
| 반응물 | DOPS cholesterol | HCID 131731632 | — |
| 용매 | Water | HCID 962 | — |
| 생성물 | Droxidopa | HCID 92974 | — |
반응 단계
Cochleates containing OVA were prepared from unilamellar liposomes comprising a 9:1 mixture (w/w) of synthetic ester lipid 1,2-Dioleoyl-sn-Glycero-3-[Phospho-L-Serine] sodium salt (DOPS lyophilized powder; obtained from Avanti Polar Lipids Inc.; Alabaster, Ala., USA; MW of 810.04; cat #830035P, Lot #181PS-214) and cholesterol (Sigma Chemical Co.; Cat # C8667), by the standard cochleate method of direct addition of CaCl2 as described (Gould-Fogerite and Mannino, 1993). Briefly, a dried film of 20 mg mixture of the DOPS-cholesterol was hydrated in 1 ml of OVA stock solution (10 mg OVA/ml water) and converted to unilamellar liposomes by bath sonication, by avoiding exposure to air as described (Jin et al., 2000). Ten microliter aliquots of 0.1 M CaCl2 stock solution were added to the liposome suspension with mixing in between each addition, till the total concentration of calcium ions equaled to one half the molar concentration of DOPS constituting the liposomes, and then additional CaCl2 was added to achieve a 3 mM excess over that already added, as described (Gould-Fogerite and Mannino, 1993).
출처 및 근거
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| 특허 번호 | US08758763B2 |
|---|
| 출처 데이터셋 | uspto-grants-2014_06 |
|---|
| ORD ID | ord-69ecc6a4f49b4677afae8d6f72ac3cfc |
|---|
| 출처 메모 | uspto-grants-2014_06 |
|---|